Guangzhou Pharmaceutical Group has recently formed several partnerships across Central Asia to bolster its strategic growth in pharmaceutical trade, cross-border supply networks, localized manufacturing, and healthcare investments.
The company’s subsidiary, Baiyunshan Hanfang, is collaborating with Kazakhstan’s Kolon Pharma to produce anti-tumor active pharmaceutical ingredients, enhancing upstream industry cooperation. Additionally, Baiyunshan Tianxin Pharmaceutical is working with Uzbekistan’s ADN Pharm-Sanoat on drug registration, distribution channels, and establishing local brands.
A preliminary agreement has also been reached with Uzbekistan’s Omon Med Pharm to develop new approaches to joint manufacturing facilities and joint research and development projects.
On the investment side, the company has partnered with Samruk-Kazyna, Kazakhstan’s sovereign wealth fund, to tap into its resources across sectors like energy, logistics, and chemicals, aiming to deepen cooperation in pharmaceutical trading, industrial investments, and local operations.
In logistics and supply chain management, Guangzhou Pharma is teaming up with China-Uzbekistan Logistics, which manages bonded warehouses for Asia-Europe railway container transport and boasts a comprehensive cold chain logistics system. Their collaboration focuses on cold chain transportation, bonded warehousing, and cross-border distribution services.